Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Net Margin: 2019-2025

Historic Net Margin for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -1,395.29%.

  • Avidity Biosciences' Net Margin rose 203648.00% to -1,395.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,628.53%, marking a year-over-year increase of 13844.00%. This contributed to the annual value of -2,955.44% for FY2024, which is 74178.00% down from last year.
  • As of Q3 2025, Avidity Biosciences' Net Margin stood at -1,395.29%, which was up 65.74% from -4,072.37% recorded in Q2 2025.
  • Avidity Biosciences' Net Margin's 5-year high stood at -881.69% during Q1 2021, with a 5-year trough of -7,332.36% in Q1 2025.
  • For the 3-year period, Avidity Biosciences' Net Margin averaged around -3,094.49%, with its median value being -2,751.39% (2023).
  • Over the last 5 years, Avidity Biosciences' Net Margin had its largest YoY gain of 203,648bps in 2025, and its largest YoY loss of 539,180bps in 2025.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Net Margin stood at -2,078.40% in 2021, then soared by 25,634bps to -1,822.07% in 2022, then plummeted by 92,933bps to -2,751.39% in 2023, then tumbled by 69,489bps to -3,446.28% in 2024, then surged by 203,648bps to -1,395.29% in 2025.
  • Its last three reported values are -1,395.29% in Q3 2025, -4,072.37% for Q2 2025, and -7,332.36% during Q1 2025.